Cochrane · systematic review · CD010770
Selective progesterone receptor modulators (SPRMs) for uterine fibroids
Murji, A, Whitaker, L, Chow, TL, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 8.3%Very low 0 · 0%Low 2 · 16.7%Moderate 9 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
SPRM versus placebo
Population: women with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life: change in symptom severity score SPRM vs placebo | no estimate extracted | 4 studies · 171 participants | Moderate Downgraded: publication bias |
Quality of life: change in health‐related quality of life score SPRM vs placebo | no estimate extracted | 4 studies · 200 participants | Moderate Downgraded: publication bias |
Abnormal uterine bleeding: change in menstrual blood loss SPRM vs placebo | no estimate extracted | 3 studies · 310 participants | Moderate Downgraded: publication bias |
Abnormal uterine bleeding: amenorrhoea SPRM vs placebo | OR 82.5 [37.1, 183.9] | 7 studies · 590 participants | Moderate Downgraded: publication bias |
Pelvic pain (measured subjectively) SPRM vs placebo | no estimate extracted | 7 studies · 629 participants | Ungraded |
Adverse effects: SPRM‐associated endometrial changes SPRM vs placebo | OR 15.12 [6.45, 35.47] | 5 studies · 405 participants | Low Downgraded: publication bias |
SPRM versus leuprolide acetate for uterine fibroids
Population: uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life: change in symptom severity score SPRM vs leuprolide acetate | no estimate extracted | 1 study · 281 participants | Moderate Downgraded: publication bias |
Quality of life: change in health‐related quality of life score SPRM vs leuprolide acetate | no estimate extracted | 1 study · 281 participants | Moderate Downgraded: publication bias |
Abnormal uterine bleeding: change in menstrual blood loss (measured using PBAC score) SPRM vs leuprolide acetate | no estimate extracted | 1 study · 281 participants | Low Downgraded: publication bias |
Abnormal uterine bleeding: amenorrhoea SPRM vs leuprolide acetate | OR 1.14 [0.6, 2.16] | 1 study · 280 participants | Moderate Downgraded: publication bias |
Pelvic pain (measured using McGill Pain Questionnaire: range 0 to 45) SPRM vs leuprolide acetate | no estimate extracted | 1 study · 281 participants | Moderate Downgraded: publication bias |
Adverse effects: SPRM‐associated endometrial changes SPRM vs leuprolide acetate | OR 10.45 [5.38, 20.33] | 1 study · 301 participants | Moderate Downgraded: publication bias |